The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / New Findings on COVID-19 Vaccination, Race & More Shared in 1st Plenary Session

New Findings on COVID-19 Vaccination, Race & More Shared in 1st Plenary Session

December 9, 2021 • By Thomas R. Collins

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Patients in the risankizumab group had significantly higher rates of ACR20, 50 and 70 responses at 24 weeks after the start of treatment (P<0.001) than patients in the placebo group. They also had higher scores on the Psoriasis Area Severity Index (PASI) 90 (P<0.001) and better performance on the Health Assessment Questionnaire-Disability Index (HAQ-DI; P<0.001) than patients in the placebo group.

You Might Also Like
  • ACR Convergence 2020 Kicks Off: Plenary session speakers highlight racial differences in lupus & COVID-19-related findings
  • Research on SLE, pJIA & More Highlighted in 2nd ACR Convergence 2021 Plenary Session
  • COVID-19 Perspectives Shared in ACR Convergence Opening Session
Also By This Author
  • Turbocharge Your Cell Analysis with Mass Cytometry

Those in the treatment group also had significantly higher rates of minimal disease activity at 24 weeks, Dr. Ostor said.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Disparity by Race & Neighborhood

Dr. Ram Singh

From 1999 to 2019, 8,899 deaths in the U.S. were attributed to lupus nephritis, with death rates due to the condition declining by 27% during this time.3 But from 2014 to 2019, the death rates began to rise, said Ram Singh, MD, professor of medicine at the University of California, Los Angeles.

The findings came from an analysis of data from the U.S. Centers for Disease Control and Prevention’s WONDER database on public health.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Researchers also found that, compared with white people, death rates from lupus nephritis were 6.1 times higher over that period for Black people, about 2.2 times higher for Hispanics, about 2.0 times higher for Asians and about 2.7 times higher for Native Americans.

Looking at urbanization, researchers found the highest death rates from lupus nephritis were in large, central metro areas—essentially inner cities—while living in large, fringe metropolitan area—essentially suburbs—was associated with the lowest death rates.

They also found race had a different effect on the risk of death from lupus nephritis in different urbanization areas. Example: Hispanics had a much higher mortality rate in large central metro areas than they did in all other urbanization zones, while Black race had relatively little effect on lupus nephritis mortality risk across urbanization zones.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Both race and residence are independently associated with lupus nephritis mortality, according to Dr. Singh. “Urbanization is an effective modifier of race/ethnicity’s effect on lupus nephritis mortality, suggesting neighborhood environmental factors [into] health outcomes,” he said.

Abatacept & RA Prevention

Dr. Juergen Rech

Abatacept improved subclinical inflammation in patients at risk of developing RA, with longer-term results awaited, according to findings presented by Juergen Rech, MD, a rheumatologist and researcher at the University Clinic Erlangen, Germany.4

The therapy targets the window of opportunity when patients experience arthralgias and have signs of subclinical inflammation, but don’t yet have any current or previous signs of swelling, don’t have a diagnosis of clinical arthritis and haven’t received glucocorticoids or treatment with disease-modifying anti-rheumatic drugs (DMARDs).

Pages: 1 2 3 4 | Single Page

Filed Under: ACR Convergence, Conditions, Meeting Reports, Rheumatoid Arthritis, Spondyloarthritis Tagged With: ACR Convergence 2021, ACR Convergence 2021 – RA, COVID-19, disparity

You Might Also Like:
  • ACR Convergence 2020 Kicks Off: Plenary session speakers highlight racial differences in lupus & COVID-19-related findings
  • Research on SLE, pJIA & More Highlighted in 2nd ACR Convergence 2021 Plenary Session
  • COVID-19 Perspectives Shared in ACR Convergence Opening Session
  • Updates on JAK Inhibitor Safety, COVID-19 Vaccination in Immunosuppressed Patients & More

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)